Clinical Trial Update: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) [Phase 3]

View source ↗

Summary

A Phase 3 study of Remternetug (LY3372993) for early Alzheimer's disease (TRAILRUNNER-ALZ 3) is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Remternetug (LY3372993)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING